Search Results

You are looking at 111 - 120 of 515 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

The First Documented Case of High-Grade Synovial Cell Sarcoma of the Rectum

Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette

higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100

Full access

Multidisciplinary Management of Pancreatic Cancer

Margaret A. Tempero

pancreatic cancer, 80% of patients are diagnosed with advanced unresectable disease; 80% experience relapse after resection and adjuvant therapy; and median overall survival (OS) of patients with untreated metastatic disease is only 3 months. The “cure rate

Full access

Incorporating New Systemic Therapies in Kidney Cancer Treatment

Eric Jonasch

in Oncology (NCCN Guidelines) for Kidney Cancer. Adjuvant Therapy Three trials have been conducted in the adjuvant setting, 2 of which (ASSURE and PROTECT) showed negative results for adjuvant sunitinib, sorafenib, and pazopanib. A third trial

Full access

Ten Years of Progress in Colon Cancer Therapy

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Locally Recurrent Endometrial Cancer: A Case Report

Srinivas K. Tantravahi, and Theresa L. Werner

pathologically staged as FIGO stage IA (pT1a pN0 Mx). She received no adjuvant therapy. She returned 3 months later with recurrent vaginal bleeding. A 2-cm friable mass was visualized at the apex of the vaginal cuff on pelvic examination and was resected

Full access

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

. 29. Gunderson LL Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy . Int J Radiat Oncol Biol Phys 1982 ; 8 : 1

Full access

Take Your Medicine

Harold J. Burstein

percentage. Of course, a few caveats are warranted. The bulk of these reports are derived from studies of women taking adjuvant therapy for hormone receptor-positive breast cancer. Such patients often have a favorable prognosis and might reasonably be

Full access

Management of a Patient With Advanced BRAF-Mutant Melanoma

Michelle T. Ashworth and Adil Daud

and MEK inhibitors, and effective adjuvant therapies can be expected to increase the impact of accurate staging with SLNB on overall survival. At the time of metastasis to lymph nodes in 2002, the patient was treated with complete lymphadenectomy

Full access

Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma

Yongzhu He, Laihui Luo, Renfeng Shan, Junlin Qian, Lifeng Cui, Zhao Wu, Shuju Tu, WenJian Zhang, Wei Lin, Hongtao Tang, Zeyu Huang, Zhigang Li, Shengping Mao, Hui Li, Zemin Hu, Liping Liu, Wei Shen, Kun He, and Yong Li

-based calculator for the postoperative nomogram to better distinguish patients in different risk levels and predict DFS and OS. In recent years, whether high-risk patients prone to early tumor recurrence should receive postoperative adjuvant therapy has become a

Full access

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Kari Kendra, Jayanthi Lea, Nita Lee, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole McMillian, and Sara Espinosa

(SLN) biopsy or ipsilateral IF lymphadenectomy; the latter should be performed if no SLN(s) is/are detected. Adjuvant therapy is informed by primary tumor risk factors and nodal surgical pathology. Patients with anterior or posterior central vulvar